Regenerx Biopharmaceuticals (RGRX) Debt by Year
Regenerx Biopharmaceuticals held $291K in cash and equivalents at the end of fiscal year 2022, and long-term debt is not reported for that period. The table below carries 13 fiscal years, from 2010 to 2022, and the quarters Regenerx Biopharmaceuticals has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
RGRX Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K | FY1010-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $291K-76.4% | $1.2M+187.8% | $428K-33.1% | $640K+169.7% | $237K+30.6% | $182K-76.4% | $769K+142.3% | $318K-62.4% | $844K+13284.8% | $6K-95.6% | $142K+22.2% | $116K-96.9% | $3.8M |
RGRX Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q1'2310-Q | Q4'2210-Q | Q3'2210-Q | Q2'2210-Q | Q1'2210-Q | Q4'2110-K | Q3'2110-Q | Q2'2110-Q | Q1'2110-Q | Q4'2010-K | Q3'2010-Q | Q2'2010-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $102K-89.0% | $291K-76.4% | $478K-68.6% | $707K-65.1% | $925K+345.7% | $1.2M+187.8% | $1.5M+997.5% | $2.0M+436.4% | $208K-66.2% | $428K-33.1% | $139K-84.3% | $378K-67.7% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Regenerx Biopharmaceuticals financials
Frequently Asked Questions
What was Regenerx Biopharmaceuticals's long-term debt in fiscal year 2022?
Regenerx Biopharmaceuticals held $291K in cash and equivalents at the end of fiscal year 2022, and long-term debt is not reported for that period.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Regenerx Biopharmaceuticals (RGRX) reported on that line in every period on record.